Technology | Endoscopes | March 26, 2018

Auris Health Unveils FDA-Cleared Monarch Platform for Robotic Bronchoscopy

Flexible remote-controlled technology provides continuous visualization of small, hard-to-reach lung nodules

Auris Health Unveils FDA-Cleared Monarch Platform for Robotic Bronchoscopy

March 26, 2018 — Auris Health Inc. announced U.S. Food and Drug Administration (FDA) clearance of the company’s Monarch Platform. The Monarch Platform integrates the latest advancements in robotics, software, data science and endoscope innovation, with the goal of improving patient outcomes, enhancing physician capabilities, and lowering costs to the healthcare system.

Auris’ first targeted disease state is lung cancer. The FDA cleared the platform for diagnostic and therapeutic bronchoscopic procedures. The goal of the technology is to enable more accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.

Founded and led by surgical robotics pioneer Frederic Moll, M.D., Auris has raised more than $500 million in equity capital from leading technology investors including Mithril Capital Management, Lux Capital, Coatue Management and Highland Capital.

There are a variety of diagnostic options currently available for lung cancer, but all have limitations in accuracy, safety, or invasiveness. These limitations can lead to false positives, false negatives or side effects such as pneumothorax (collapsed lung) and hemorrhage, which may increase healthcare costs and extend hospital stays.

“Four hundred fifty people die every day in the United States due to lung cancer. It is the No. 1 cancer killer of both men and women in the world. Lung cancer screening has given us an opportunity to save some of these people by diagnosing the cancer early, while we have a chance to cure it. Despite the benefit, we still are limited by the current technology in making a diagnosis," said Michael Simoff, M.D., director of interventional pulmonology at Henry Ford Health System in Detroit. "The development of new advanced technology, like the Monarch Platform, could allow us the opportunity to make the diagnosis early, which translates directly to saving lives.”

The Monarch Platform is a flexible endoscopic technology that holds promise to fight lung cancer by allowing physicians to diagnose, and eventually treat, hard-to-reach, small peripheral nodules with greater precision. The platform utilizes a familiar controller-like interface that physicians use to navigate the flexible robotic endoscope to the periphery of the lung with improved reach, vision and control. Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3-D models of the patient’s own lung anatomy, the Monarch Platform provides physicians with continuous bronchoscope vision throughout the entire procedure.

For more information: www.aurishealth.com

 

Related Content

New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Researchers Use Artificial Intelligence to Deliver Personalized Radiation Therapy
News | Radiation Therapy | July 09, 2019
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to...
SIIM and ACR Host Machine Learning Challenge for Pneumothorax Detection and Localization
News | Artificial Intelligence | June 03, 2019
The Society for Imaging Informatics in Medicine (SIIM) and the American College of Radiology (ACR) are collaborating...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Vast Majority of Heavy Smokers Not Screened for Lung Cancer
News | Lung Cancer | May 29, 2019
Out of more than 7 million current and former heavy smokers, only 1.9 percent were screened for lung cancer in 2016...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
FDA Approves Zebra Medical Vision's HealthPNX AI Chest X-ray Triage Product
Technology | Artificial Intelligence | May 13, 2019
Zebra Medical Vision has received U.S. Food and Drug Administration (FDA) 510(k) clearance for HealthPNX, an artificial...
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
Physicians, Patients Talking Less About Lung Cancer Screening
News | Lung Cancer | April 29, 2019
Smoking rates are down nationally, but so are discussions among physicians and smokers about lung cancer screening,...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...